## 4574

## FGF Receptor 3 (C51F2) Rabbit mAb



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

## For Research Use Only. Not for Use in Diagnostic Procedures.

<b>Applications:</b> W, IP, IHC-P, IF-IC	Reactivity: H	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 165, 145 and 125	<b>Source/Isotype:</b> Rabbit IgG	UniProt ID: #P22607	Entrez-Gene Id: 2261
Product Usage Information		<b>Application</b> Western Blotting Immunoprecipitation Immunohistochemis	try (Paraffin)			<b>Dilution</b> 1:1000 1:50 1:50
_		Immunofluorescence (Immunocytochemistry)				1:200
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.				
		For a carrier free (BSA and azide free) version of this product see product #94065.				
Specificity/Sensitivity		FGF Receptor 3 (C51F2) Rabbit mAb detects endogenous levels of FGF Receptor 3 protein. This antibody does not cross-react with other related family members.				
Source / Purification		Monoclonal antibody is produced by immunizing animals with a GST-FGFR-3 cytoplasmic domain fusion protein.				
Background		Fibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through cell surface receptor tyrosine kinases. There are four members of the FGF receptor family: FGFR1 (flg), FGFR2 (bek, KGFR), FGFR3, and FGFR4. Each receptor contains an extracellular ligand-binding domain, a transmembrane domain, and a cytoplasmic kinase domain (1). Following ligand binding and dimerization, the receptors are phosphorylated at specific tyrosine residues (2). Seven tyrosine residues in the cytoplasmic tail of FGFR1 can be phosphorylated: Tyr463, 583, 585, 653, 654, 730, and 766. Tyr653 and Tyr654 are important for catalytic activity of activated FGFR and are essential for signaling (3). The other phosphorylated tyrosine residues may provide docking sites for downstream signaling components, such as Crk and PLCγ (4,5).				
		Activating mutations within fibroblast growth factor receptor 3 (FGFR-3) are responsible for human skeletal dysplasias including achondroplasia and the neonatal lethal syndromes thanatophoric dysplasia types I and II (6). Several of these same FGFR-3 mutations as well as overexpression of FGFR-3 proteins have also been identified somatically in human cancers, including multiple myeloma, bladder carcinoma and cervical cancer (7). Thus, FGFR-3 may represent a potential target for therapy.				
Background Ref	erences	<ol> <li>Powers, C.J. et al. (2000) Endocr Relat Cancer 7, 165-97.</li> <li>Reilly, J.F. et al. (2000) J Biol Chem 275, 7771-8.</li> <li>Mohammadi, M. et al. (1996) Mol Cell Biol 16, 977-89.</li> <li>Mohammadi, M. et al. (1991) Mol Cell Biol 11, 5068-78.</li> <li>Larsson, H. et al. (1999) J Biol Chem 274, 25726-34.</li> <li>Wilkie, A.O. et al. (2002) Am J Med Genet 112, 266-78.</li> <li>Miyake, M. et al. (2007) Biochem Biophys Res Commun 362, 865-71.</li> </ol>				
Species Reactivi	ty	Species reactivity is c	etermined by testing	in at least one approve	ed application (e.g.,	western blot).
Western Blot Bu	ffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				

**Applications Key** 

 $\textbf{W:} \ We stern \ Blotting \ \textbf{IP:} \ Immunoprecipitation \ \textbf{IHC-P:} \ Immunohistochemistry \ (Paraffin) \ \textbf{IF-IC:}$ 

Immunofluorescence (Immunocytochemistry)

Cross-Reactivity Key H: Human

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

## **Limited Uses**

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.